Vaxcyte, Inc. (NASDAQ:PCVX) is Windsor Advisory Group LLC's 4th Largest Position

Windsor Advisory Group LLC raised its position in Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 72.5% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 39,223 shares of the company's stock after acquiring an additional 16,479 shares during the quarter. Vaxcyte accounts for about 3.7% of Windsor Advisory Group LLC's investment portfolio, making the stock its 4th largest holding. Windsor Advisory Group LLC's holdings in Vaxcyte were worth $3,211,000 at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. Whipplewood Advisors LLC purchased a new position in shares of Vaxcyte in the fourth quarter valued at $28,000. Smartleaf Asset Management LLC lifted its holdings in Vaxcyte by 188.4% in the 4th quarter. Smartleaf Asset Management LLC now owns 398 shares of the company's stock worth $33,000 after buying an additional 260 shares in the last quarter. National Bank of Canada FI acquired a new position in Vaxcyte in the 4th quarter worth $41,000. Blue Trust Inc. boosted its position in Vaxcyte by 100.0% in the 4th quarter. Blue Trust Inc. now owns 742 shares of the company's stock valued at $61,000 after buying an additional 371 shares during the last quarter. Finally, Assetmark Inc. grew its stake in shares of Vaxcyte by 77,500.0% during the fourth quarter. Assetmark Inc. now owns 776 shares of the company's stock valued at $64,000 after acquiring an additional 775 shares in the last quarter. Hedge funds and other institutional investors own 96.78% of the company's stock.

Insider Activity at Vaxcyte

In other Vaxcyte news, COO Jim Wassil sold 8,000 shares of the stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $73.27, for a total value of $586,160.00. Following the sale, the chief operating officer now directly owns 154,931 shares of the company's stock, valued at $11,351,794.37. This trade represents a 4.91% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Insiders own 3.10% of the company's stock.

Analyst Upgrades and Downgrades

Several research analysts recently commented on the company. Evercore ISI upgraded Vaxcyte to a "strong-buy" rating in a research note on Monday, March 31st. Needham & Company LLC reaffirmed a "buy" rating and issued a $90.00 target price on shares of Vaxcyte in a research report on Tuesday, April 8th. Guggenheim reissued a "buy" rating and set a $160.00 price target on shares of Vaxcyte in a research report on Wednesday, March 12th. Cantor Fitzgerald initiated coverage on shares of Vaxcyte in a report on Tuesday, April 22nd. They issued an "overweight" rating on the stock. Finally, Bank of America reduced their price objective on shares of Vaxcyte from $157.00 to $137.00 and set a "buy" rating on the stock in a research note on Tuesday, April 1st. Nine research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, Vaxcyte has an average rating of "Buy" and a consensus price target of $136.50.

Vaxcyte Stock Up 0.6%

Shares of NASDAQ:PCVX opened at $32.03 on Tuesday. The firm has a 50-day simple moving average of $41.73 and a 200 day simple moving average of $70.94. Vaxcyte, Inc. has a fifty-two week low of $27.66 and a fifty-two week high of $121.06. The company has a market cap of $4.13 billion, a PE ratio of -6.96 and a beta of 1.27.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last posted its earnings results on Wednesday, May 14th. The company reported ($1.04) EPS for the quarter, missing the consensus estimate of ($1.02) by ($0.02). During the same quarter in the prior year, the company earned ($0.85) earnings per share. As a group, research analysts forecast that Vaxcyte, Inc. will post -4.21 EPS for the current fiscal year.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.